Annexon Inc - ESG Rating & Company Profile powered by AI
Other corporations in the scoring peer group for Annexon Inc are shown. If you work at Annexon Inc and you would like to licence your Sustainability rating, please contact us. This report of Annexon Inc is assembled by All Street Sevva using cutting edge NLP.
Annexon Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.4; made up of an environmental score of 8.0, social score of 6.4 and governance score of 4.8.
6.4
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 389 | WuXi Biologics (Cayman) Inc | 6.6 | High |
| 401 | Oxford Cannabinoid Technologies Holdings PLC | 6.5 | High |
| 402 | Annexon Inc | 6.4 | High |
| 402 | Capricor Therapeutics Inc | 6.4 | High |
| 402 | Alembic Pharmaceuticals Ltd | 6.4 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Annexon Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Annexon Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Annexon Inc report the average age of the workforce?
Sign up for free to unlockDoes Annexon Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Annexon Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Annexon Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Annexon Inc offer flexible work?
Sign up for free to unlockDoes Annexon Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Annexon Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Annexon Inc conduct supply chain audits?
Sign up for free to unlockDoes Annexon Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Annexon Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Annexon Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Annexon Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Annexon Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Annexon Inc disclose water use targets?
Sign up for free to unlockDoes Annexon Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Annexon Inc have a product recall in the last two years?
Sign up for free to unlockDoes Annexon Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Annexon Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Annexon Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Annexon Inc disclose parental leave metrics?
Sign up for free to unlockDoes Annexon Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Annexon Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Annexon Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Annexon Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Annexon Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Annexon Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Annexon Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Annexon Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Annexon Inc disclose its waste policy?
Sign up for free to unlockDoes Annexon Inc report according to TCFD requirements?
Sign up for free to unlockDoes Annexon Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Annexon Inc disclose energy use targets?
Sign up for free to unlockDoes Annexon Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Annexon Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Annexon Inc
These potential risks are based on the size, segment and geographies of the company.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune and neurodegenerative diseases. It focuses on the treatment of body, brain, and eye disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, which has completed Phase 1b clinical trials to treat patients with guillain- barré syndrome; and ANX007, which has completed Phase 1b clinical trials to treat patients with glaucoma. The company's candidates also comprise ANX005 that has completed preclinical trials to treat patients with warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis; ANX007, which has completed preclinical trials for the treatment of geographic atrophy; and ANX009 that has completed preclinical trials for the treatment of systemic autoimmune diseases. The company was founded in 2011 and is headquartered in South San Francisco, California.